Healthy volunteers to test how new drug enters the body
NCT ID NCT07545590
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study will test how eltrekibart, an experimental drug, is absorbed when injected under the skin compared to when given through a vein. Sixty healthy adults will receive a single dose and be monitored for about 17 weeks. The goal is to gather safety and absorption data, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- eltrekibart (LY3041658)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lilly Centre for Clinical Pharmacology
RECRUITINGSingapore, 138623, Singapore
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test